Read more about the case.

News and Analysis from the Center

• Access to Abortion Medication Remains Unchanged After Ruling by the U.S. Supreme Court, 06.13.24
• Press release: Supreme Court Ruling Maintains Access to Mifepristone, 06.13.24
• Supreme Court Will Hear Case that Could Undermine Abortion Pill Access Nationwide, 12.13.23
• Court Rules to Reinstate Burdensome Restrictions on Abortion Medication but Not to Revoke FDA Approval of the Drug, 08.16.23
• Health, Pharmaceutical and Legal Experts Urge Circuit Court to Reverse Order Attempting to Block FDA’s Approval of Abortion Drug, 05.08.23
• Press release: Supreme Court Prevents Radical Abortion Pill Ruling From Taking Effect for Now, 04.14.23
• Press release: Appellate Court Upholds Most of Radical Decision Threatening Abortion Pill, 04.13.23
• The Center and Movment Partners Urge Court to Block Unprecedented Ruling Rejecting FDA’s Approval of Abortion Drug, 04.12.23
• Texas Court’s Radical Decision Attempts to Block FDA Approval of a Medication Abortion Drug Used for More Than 20 Years, 04.07.23
• Press release: Federal Court Rules to Pull Abortion Drug Off Market Nationwide, 04.07.23
• Nationwide Threat to Medication Abortion, 02.01.23

Media Highlights: Supreme Court Ruling

• The United States Supreme Court ruled June 13 that the plaintiffs suing the Food and Drug Administration (FDA) did not have standing to bring the case, leaving access to the popular abortion medication mifepristone unchanged. Read media coverage of the ruling here.

Media Highlights

• To view broadcast, print and online media coverage of the case, click here.

More About the Case

• Alliance for Hippocratic Medicine v. FDA: Complete Case Information